Additive preventive effect of influenza and pneumococcal vaccines in elderly persons

@article{Christenson2004AdditivePE,
  title={Additive preventive effect of influenza and pneumococcal vaccines in elderly persons},
  author={B. Christenson and J. Hedlund and P. Lundbergh and A. Örtqvist},
  journal={European Respiratory Journal},
  year={2004},
  volume={23},
  pages={363 - 368}
}
In 1999, all individuals ≥65 yrs of age (n=258,754) in Stockholm County, Sweden, were offered influenza and pneumococcal vaccination in a prospective study on the effectiveness of these vaccines in reducing the need for hospital treatment and death due to influenza, pneumonia and invasive pneumococcal disease (IPD). Data on hospitalisation and mortality during 1 yr were obtained from the administrative database in Stockholm County Council. Vaccination was performed in 124,702 (48%) subjects; 72… Expand
Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity
TLDR
The additive effect of the two vaccines in the elderly, which was associated with a reduced risk in hospitalisation and a reduction in mean LOHS in seasons with low influenza activity, is confirmed. Expand
Additive preventive effect of influenza and pneumococcal vaccines in the elderly
TLDR
An additive effect was observed in the prevention of all-cause mortality with influenza and pneumococcal vaccines given together in elderly people, including in those with underlying chronic disease. Expand
Preventive effects of influenza and pneumococcal vaccination in the elderly – results from a population-based retrospective cohort study
TLDR
A retrospective cohort study of 138,877 individuals aged ≥60 y in Germany found a rise in influenza-like illness and acute respiratory infections in both years and an increased 90-d mortality after hospital-treated pneumonia in vaccinees in 2015. Expand
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
TLDR
It is suggested that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. Expand
Prospective Cohort Study on the Effectiveness of Influenza and Pneumococcal Vaccines in Preventing Pneumonia Development and Hospitalization
TLDR
F influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI during the influenza epidemic period in 2013 to 2014. Expand
Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study
TLDR
PPSV23 vaccination is likely effective in reducing incidence of pneumococcal CAP in older individuals, although its preventive effect for all-cause CAP has not been achieved. Expand
Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
TLDR
The results indicate that the 23-valent PPV effectively prevented pneumococcal pneumonia (with or without bacteremia) and decreased the rates of overall pneumonia and of mortality due to pneumonia in older adults, providing new arguments for systematic vaccination in the elderly population. Expand
Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
TLDR
Patients with CAP who had prior PPV had about a 40% lower rate of mortality or ICU admission compared with those who were not vaccinated, providing additional support for recommending PPV to those at risk of pneumonia. Expand
The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study
TLDR
Assessing health care utilisation and costs due to influenza- or pneumococcal-associated diseases, respiratory infections, and sepsis in the elderly using real-world data on both, outpatient and inpatient care found Influenza and pneumococci-vaccinated individuals can be cost-saving in selective seasons and health care divisions. Expand
Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study
TLDR
Pneumococcal vaccination coverage of hospitalized elderly people is low and activities that encourage healthcare workers to proactively propose vaccination might be useful to reduce the burden of pneumococcal disease in the community. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up.
TLDR
The incidence of hospital admissions during 1 year after the vaccination campaign was significantly lower in the vaccinated than in the unvaccinated cohort for influenza, and the in-hospital mortality was lower for pneumonia, COPD, and cardiac failure. Expand
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study
TLDR
Findings show that general vaccination leads to substantial health benefits and to a reduction of mortality from all causes in this age group. Expand
Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly.
TLDR
The effectiveness determined during the peak period of virus circulation is felt to be a conservative estimate, since agents other than influenza are responsible for pneumonia and influenza hospitalizations, even during times of peak influenza activity. Expand
The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease.
TLDR
Pneumococcal vaccination is associated with substantial benefits for elderly persons with chronic lung disease and both vaccinations together demonstrated additive benefits. Expand
Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection
TLDR
The influenza and pneumococcal-vaccine recipients were older and had significantly more chronic lung and heart conditions than the unvaccinated cohort. Expand
Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.
TLDR
Pneumococcal vaccination significantly reduced the incidence of pneumococcal pneumonia in elderly persons at increased risk for contracting pneumonia and may be the best strategy to prevent this rather common and often fatal disease. Expand
The clinical effectiveness of pneumococcal vaccine in the elderly.
TLDR
The clinical effectiveness ofneumococcal vaccine in preventing pneumococcal infection in the immunocompetent elderly approximates the vaccine's effectiveness in the general immunocmpetent population. Expand
The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly
TLDR
The clinical effectiveness ofneumococcal vaccine in preventing pneumococcal infection in the immunocompetent elderly approximates the vaccine's effectiveness in the general immunocmpetent population. Expand
Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic.
TLDR
Influenza vaccine is effective in reducing hospital admissions for influenza, pneumonia, bronchitis and emphysema, and effectiveness is comparable to that observed for influenza and pneumonia admissions in North America. Expand
The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.
TLDR
Pneumococcal vaccination of elderly persons with chronic lung disease was associated with fewer hospitalizations for pneumonia, fewer deaths, and direct medical care cost savings. Expand
...
1
2
3
4
...